Evidence Level
Huperzine A is a natural acetylcholinesterase inhibitor derived from the Chinese club moss *Huperzia serrata*. It has been extensively studied for its cognitive benefits, particularly in neurodegenerative and psychiatric conditions. A 2013 systematic review and meta-analysis by Yang et al. (2013) of 20 randomized controlled trials (n=1823) demonstrated that Huperzine A significantly improved cognitive function, daily living activities, and global clinical assessment in Alzheimer's disease patients compared to placebo or other treatments. Similarly, a 2009 meta-analysis by Wang et al. (2009) of four randomized trials (n=645) found significant improvements in MMSE and ADL scores for Alzheimer's patients with no serious adverse effects.
Beyond Alzheimer's disease, Huperzine A has shown efficacy in other cognitive conditions. A 2019 systematic review and meta-analysis by Huang et al. (2019) of nine RCTs found that Huperzine A significantly improved memory quotient (MQ) and MMSE scores compared to placebo in patients with mild cognitive impairment, though side effects were mild. Additionally, a 2016 systematic review and meta-analysis by Zheng et al. (2016) of 12 RCTs (n=1117) found that adjunctive Huperzine A significantly improved cognitive function in patients with schizophrenia spectrum disorders compared to placebo or antipsychotic treatment alone.
Huperzine A's dual mechanism—acetylcholinesterase inhibition and NMDA receptor antagonism—contributes to its broader neuroprotective effects. However, most high-quality trials are concentrated in Chinese literature, and large Western multicenter studies remain limited.